Results 131 to 140 of about 3,802,616 (346)

A monoclonal antibody collection for C. difficile typing ?

Gut Pathogens
Clostridioides difficile is the leading cause of antibiotic-associated diarrhea and pseudomembranous colitis in adults. Various C. difficile strains circulate currently, associated with different outcomes and antibiotic resistance profiles. However, most
Lise Hunault, Patrick England, Frédéric Barbut, Bruno Iannascoli, Ophélie Godon, François Déjardin, Christophe Thomas, Bruno Dupuy, Chunguang Guo, Lynn Macdonald, Guy Gorochov, Delphine Sterlin, Pierre Bruhns   +12 more
doaj   +1 more source

The Role of Antibodies in Experimental Drug Resistance of Trypanosoma Equiperdum [PDF]

, 1946
R. Schnitzer, Lillian C. Lafferty, Margaret Buck   +2 more
openalex   +1 more source

Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cancer

Molecular Oncology, EarlyView.
C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald, Anna M. Reagan, Charles J. Bailey, Mei Gao, Muqiang Gao, Angelica L. Solomon, Michael J. Cavnar, Prakash K. Pandalai, Mautin T. Barry‐Hundeyin, Megan M. Harper, Justin A. Rueckert, Ángela Turrero, Araceli Tobio, Anxo Vidal, Daniel Roca‐Lema, Elia Álvarez‐Coiradas, Pablo Garrido, Laureano Simón, Joseph Kim   +18 more
wiley   +1 more source

ON THE PRESENCE IN ANTIPNEUMOCOCCUS SERUM OF TYPE-SPECIFIC PROTECTIVE ANTIBODY NOT NEUTRALIZED BY HOMOLOGOUS SPECIFIC SOLUBLE SUBSTANCE [PDF]

, 1931
Albert B. Sabin
openalex   +1 more source

BMP antagonist CHRDL2 enhances the cancer stem‐cell phenotype and increases chemotherapy resistance in colorectal cancer

Molecular Oncology, EarlyView.
Overexpression of CHRDL2 in colon cancer cells makes them more stem‐like and resistant to chemo‐ and radiotherapy. CHRDL2‐high cells have upregulation of the WNT pathway, genes involved in the DNA damage response (DDR) pathway and epithelial‐to‐mesenchymal transition (EMT). This leads to quicker repair of damaged DNA and more cell migration.
Eloise Clarkson, Annabelle Lewis
wiley   +1 more source

The Relation Between Antigen and Antibody in the Living Animal [PDF]

, 1917
Richard Weil
openalex   +1 more source

Simultaneous inhibition of TRIM24 and TRIM28 sensitises prostate cancer cells to antiandrogen therapy, decreasing VEGF signalling and angiogenesis

Molecular Oncology, EarlyView.
TRIM24 and TRIM28 are androgen receptor (AR) coregulators which exhibit increased expression with cancer progression. Both TRIM24 and TRIM28 combine to influence the response of castrate‐resistant prostate cancer (CRPC) cells to AR inhibitors by mediating AR signalling, regulation of MYC and upregulating VEGF to promote angiogenesis. Castrate‐resistant
Damien A. Leach, Nilesh Chatterjee, Kellie Spahr, Gilberto Serrano de Almeida, Anabel Varela‐Carver, Taimur T. Shah, Mathias Winkler, Hashim U. Ahmed, Charlotte L. Bevan   +8 more
wiley   +1 more source

On the Mode of Action in Vitro and the Preparation of Hemolytic Antibodies [PDF]

, 1918
A.K. Balls, John H. Korns
openalex   +1 more source

SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape

Nature, 2021
Tyler N. Starr, N. Czudnochowski, Zhuoming Liu, F. Zatta, Young-Jun Park, A. Addetia, D. Pinto, M. Beltramello, P. Hernandez, Allison J. Greaney, R. Marzi, W. Glass, Ivy Zhang, A. Dingens, John E. Bowen, M. A. Tortorici, A. Walls, Jason A. Wojcechowskyj, A. De Marco, Laura E. Rosen, Jiayi Zhou, Martin Montiel-Ruiz, Hannah Kaiser, J. Dillen, H. Tucker, J. Bassi, C. Silacci-Fregni, M. P. Housley, J. di Iulio, Gloria Lombardo, Maria L. Agostini, Nicole Sprugasci, K. Culap, S. Jaconi, M. Meury, Exequiel Dellota Jr, R. Abdelnabi, S. Foo, E. Cameroni, S. Stumpf, T. Croll, J. Nix, C. Havenar-Daughton, L. Piccoli, F. Benigni, J. Neyts, A. Telenti, Florian A. Lempp, M. Pizzuto, J. Chodera, C. Hebner, H. Virgin, S. Whelan, D. Veesler, D. Corti, J. Bloom, G. Snell   +56 more
semanticscholar   +1 more source

EMT‐associated bias in the Parsortix® system observed with pancreatic cancer cell lines

Molecular Oncology, EarlyView.
The Parsortix® system was tested for CTC enrichment using pancreatic cancer cell lines with different EMT phenotypes. Spike‐in experiments showed lower recovery of mesenchymal‐like cells. This was confirmed with an EMT‐inducible breast cancer cell line.
Nele Vandenbussche, Renske Imschoot, Béatrice Lintermans, Lode Denolf, Joachim Taminau, Charlotte Fieuws, Geert Berx, Kris Gevaert, Kathleen B. M. Claes   +8 more
wiley   +1 more source